HLA-DR Association of Anti-dsDNA and Anti-Sm Autoantibodies in Bangladeshi Patients with Systemic Lupus Erythematosus
HLA-DR Association of Anti-dsDNA and Anti-Sm Autoantibodies
DOI:
https://doi.org/10.3329/bmrcb.v48i2.62300Keywords:
systemic lupus erythematosus, major histocompatibility complex, human leukocyte antigen, Anti-dsDNA, anti-SmAbstract
Background: Rheumatic disorders are one of the largest health problems in the world in both developed and developing countries. Among systemic rheumatic disorders, systemic lupus erythematosus (SLE) is very much common. This debilitating disease most commonly affects females, especially at a young age. Though the exact etiology for the development of SLE still remains vague but genetic factors especially, HLA-DR plays an important role particularly in the development of autoantibodies in SLE cases.
Objective: This study was undertaken to find out the association of HLA-DR with anti-dsDNA and anti-Sm autoantibodies among patients with SLE.
Methods: Buccal swabs for HLA-DR typing and blood samples for detection of anti-dsDNA and anti-Sm were collected from 46 SLE cases. HLA-DR typing was carried out by end point polymerase chain reaction (PCR) with sequence specific primers. Autoantibodies were detected by using ELISA.
Results: Out of 46 cases with SLE 44 (95.65%) were female and 2 (4.35%) were male with female: male ratio was 22: 1. Their mean age at study entry was 27.05 ± 8.17 years (mean ± SD), ranging from 12.5-45 years. AntidsDNA was positive in 38 (82.61%) cases and negative in 8 (17.39%) cases. Anti-Sm was positive in 19 (41.30%) cases and negative in 27 (58.70%) cases. The most frequently identified HLA-DR was DR2 (86.96%). When Anti-dsDNA positive cases were compared with Anti-dsDNA negative cases significant association was found with HLA-DR2 (94.73% vs 50%, p value = 0.0044, pc = 0.044, RR = 18.0000). No positive association of HLA-DR was found with anti-Sm autoantibody in this study. The above data suggest that HLA-DR2 has a role in anti-dsDNA production in Bangladeshi patients with SLE.
Bangladesh Medical Res Counc Bull 2022; 48: 138-145
Downloads
32
47
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sumaiya Khatun, Humayun Sattar, Shafinaz Khan, Fatima Tuj Johora
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms.
Authors retain copyright and grant the journal right of first publication.
Articles in the Bangladesh Medical Research Council Bulletin are licensed under a Creative Commons Attribution 4.0 International License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).